Arndt Vogel, MD, Hannover Medical School, Hannover, Germany, provides an overview of efficacy and safety findings in European or North American patients in the Phase III RATIONALE-301 trial (NCT03412773), which assessed tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma (HCC). Median overall survival in the European/North American subgroup was comparable to that of the overall population. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.